CATALINA-2: A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF TORL-1-23 IN WOMEN WITH ADVANCED PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER (INCLUDING PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCERS) EXPRESSING CLAUDIN 6 (CLDN6)

Registry ID

TORL123-002

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

TORL BIOTHERAPEUTICS, LLC

Start date

2026-03-20

Last update

2024-12-16

Conditions

• OVARIAN CANCER

Related clinical trials

• A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF SACITUZUMAB TIRUMOTECAN (SAC-TMT, MK-2870) MAINTENANCE TREATMENT WITH OR WITHOUT BEVACIZUMAB VERSUS STANDARD OF CARE IN PARTICIPANTS WITH NEWLY DIAGNOSE ADVANCED HRD-NEGATIVE OVARIAN CANCER FOLLOWING FIRST-LINE PLATINUMBASED CHEMOTHERAPY (TROFUSE-021/ENGOTOV85/GOG-3102)
• A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO INVESTIGATE GSK5733584 COMPARED WITH CHEMOTHERAPY IN PARTICIPANTS WITH PLATINUM-RESISTANT OVARIAN CANCER
• A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SACITUZUMAB TIRUMOTECAN (MK-2870) MAINTENANCE TREATMENT WITH OR WITHOUT BEVACIZUMAB VERSUS STANDARD OF CARE AFTER SECOND-LINE PLATINUM-BASED DOUBLET CHEMOTHERAPY IN PARTICIPANTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER (TROFUSE-022/ENGOT-OV84/GOG-3103)
• A RANDOMIZED PHASE 2 STUDY OF OCULAR TOXICITY EVALUATION AND MITIGATION DURING TREATMENT WITH MIRVETUXIMAB SORAVTANSINE IN PATIENTS WITH RECURRENT OVARIAN CANCER WITH HIGH FOLATE RECEPTOR-ALPHA EXPRESSION
• A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF IMGN151 (ANTI-FR¿ ANTIBODY-DRUG CONJUGATE) IN ADULT PATIENTS WITH RECURRENT ENDOMETRIAL CANCER AND RECURRENT, HIGH-GRADE SEROUS EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS
• NEOCATS - NEOADJUVANT OLAPARIB COMBINATION OVARIAN CANCER TARGETED STUDY - A PHASE 2, PROOF OF CONCEPT TRIAL INVESTIGATING THE SAFETY AND EFFICACY OF THE NEOADJUVANT TRIPLET OLAPARIB, DURVALUMAB (MEDI 4736) AND BEVACIZUMAB IN ADVANCED FIGO STAGE IV HIGH GRADE SEROUS OVARIAN CANCER

View on source registry